Brief: TRACON Pharmaceuticals Initiates Phase 2 Trial Of TRC102 In Lung Cancer
02/02/2022 13:20
Feb 2 (Reuters) - TRACON Pharmaceuticals Inc TCON.O :
* TRACON PHARMACEUTICALS ANNOUNCES INITIATION OF RANDOMIZED
PHASE
2 TRIAL OF TRC102 IN LUNG CANCER SPONSORED BY NATIONAL CANCER
INSTITUTE
* TRACON PHARMACEUTICALS INC - ENROLLMENT IS EXPECTED TO
BEGIN IN
JUNE 2022 AND RESULTS ARE EXPECTED IN 2024
Source text for Eikon: ID:nGNX4WHDBM
Further company coverage: TCON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TRACON Pharmaceuticals
See all newsBrief: TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Brief: Tracon Pharmaceuticals Files For Offering Of Common Stock, Pre-Funded Warrants